Document text
Principal Investigator: Colin S. Duckett
Organization: DUKE UNIVERSITY
Fiscal Year: 2023
Award: $1,029,538
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT- Biocontainment Research Support Services Core (Core 3)
The central mission of the Duke RBL is to support the basic and translational research necessary to develop
drugs, diagnostics, and vaccines for emerging/reemerging infections and biodefense. Support through this
award will allow us to expand our existing services to refine our small animal models programs, thus providing
a wider range of services offered to the research community. It will also render our virology program more
effective, particularly through the development of a direct workflow from our clinical laboratories at Duke, in
addition to relying on third party sources, particularly for rapidly emerging viral variants. Thirdly, we will
broaden our range of immunological assays performed in our BSL-3 suites, such as live cell flow sorting and
rapid evaluation of cytokine and biomarker profiles. The goals of this Biocontainment Research Support
Services Core (Core 3) are to 1) establish, maintain, and provide small animal challenge models with BSL-3
pathogens through the Duke RBL Animal Models Research Support Services; 2) maintain and provide quality-
controlled virus inventory of Select Agents and pathogens requiring BSL-3 conditions through the Duke RBL
Virology Research Support Services; and 3) provide comprehensive immune monitoring at BSL-3 via humoral,
cellular, and biomarker analysis through the Duke RBL Immunology and Flow Cytometry Research Support
Services. Implementation of these three Aims will allow us to expand the capabilities and services that we can
offer not only to the Duke community, but also to our neighboring institutions and the national RBL network.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Animal Experimental Use><Animal Experimentation><Animal Model><Animal Models and Related Studies><Animal Research><Animals><Antibodies><Antigens><Applied Research><Applied Science><Area><Assay><Award><Basic Research><Basic Science><Bioassay><Biologic Assays><Biological Assay><Biological Markers><CHIKV><CMV><COVID-19 virus><COVID19 virus><Cell Body><Cell Isolation><Cell Segregation><Cell Separation><Cell Separation Technology><Cells><Characteristics><Chikungunya virus><Clinical><CoV-2><CoV2><Collaborations><Communities><Containment><Cricetinae><Cytomegalovirus><Development><Diagnostic><Disease><Disorder><Drugs><Ebola><Ensure><Environment><Equipment and supply inventories><Evaluation><F tularensis><F. tularensis><Fee-for-Service Plans><Fees for Service><Ferrets><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Francisella tularensis><Funding><Goals><Grippe><HCMV><HIV><Hamsters><Hamsters Mammals><History><Home><Human><Human Immunodeficiency Viruses><Immune><Immune Markers><Immune Monitoring><Immunes><Immunologic Markers><Immunologic Monitoring><Immunological Monitoring><Immunology><Immunology procedure><Immunomonitoring><Infection><Influenza><Infrastructure><Institution><Inventory><Investigators><LAV-HTLV-III><Laboratories><Laboratory Animal Models><Lymphadenopathy-Associated Virus><M tb><M tuberculosis><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><Malaria><Medication><Mice><Mice Mammals><Microbiology><Mission><Modeling><Modern Man><Murine><Mus><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Paludism><Pasteurella pestis><Pasteurella tularensis><Performance><Pharmaceutic Preparations><Pharmaceutical Preparations><Plasmodium Infections><Productivity><Publications><Recording of previous events><Research><Research Personnel><Research Support><Researchers><Resource Development><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Salivary Gland Viruses><Sampling><Scientific Publication><Secure><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Societies><Sorting><Source><TB infection><Therapeutic><Training><Training Support><Translational Research><Translational Science><Tuberculosis><United States National Institutes of Health><Universities><Vaccines><Variant><Variation><Viral><Virus><Virus-HIV><Workforce Development><Wuhan coronavirus><Y pestis><Y. pestis><Yellow fever virus><Yersinia pestis><ZIKA><animal experimentations><bio-markers><biocontainment facility><biodefense><biologic marker><biomarker><cell sorting><coronavirus disease 2019 virus><coronavirus disease-19 virus><cytokine><cytomegalovirus group><developmental><disease diagnostic><disseminated TB><disseminated tuberculosis><drug/agent><experience><flow cytophotometry><global health><hCoV19><histories><homes><immune-based biomarkers><immunogen><immunologic assay><immunologic assay/test><immunological biomarkers><immunological markers><infection due to Mycobacterium tuberculosis><lab experience><lab training><laboratory experience><laboratory training><model of animal><mouse model><mtb><murine model><nCoV2><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><new vaccines><next generation therapeutics><next generation vaccines><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><novel vaccines><novel virus><operation><operations><pathogen><pathogenic virus><programs><translation research><translational investigation><tuberculosis infection><tuberculous spondyloarthropathy><viral pathogen><virology><virus pathogen>